Literature DB >> 19729614

Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk.

Kiran Musunuru1, Marju Orho-Melander, Michael P Caulfield, Shuguang Li, Wael A Salameh, Richard E Reitz, Göran Berglund, Bo Hedblad, Gunnar Engström, Paul T Williams, Sekar Kathiresan, Olle Melander, Ronald M Krauss.   

Abstract

OBJECTIVE: Whereas epidemiological studies show that levels of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) predict incident cardiovascular disease (CVD), there is limited evidence relating lipoprotein subfractions and composite measures of subfractions to risk for CVD in prospective cohort studies. METHODS AND
RESULTS: We tested whether combinations of lipoprotein subfractions independently predict CVD in a prospective cohort of 4594 initially healthy men and women (the Malmö Diet and Cancer Study, mean follow-up 12.2 years, 377 incident cardiovascular events). Plasma lipoproteins and lipoprotein subfractions were measured at baseline with a novel high-resolution ion mobility technique. Principal component analysis (PCA) of subfraction concentrations identified 3 major independent (ie, zero correlation) components of CVD risk, one representing LDL-associated risk, a second representing HDL-associated protection, and the third representing a pattern of decreased large HDL, increased small/medium LDL, and increased triglycerides. The last corresponds to the previously described "atherogenic lipoprotein phenotype." Several genes that may underlie this phenotype-CETP, LIPC, GALNT2, MLXIPL, APOA1/A5, LPL-are suggested by SNPs associated with the combination of small/medium LDL and large HDL.
CONCLUSIONS: PCA on lipoprotein subfractions yielded three independent components of CVD risk. Genetic analyses suggest these components represent independent mechanistic pathways for development of CVD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729614      PMCID: PMC2772123          DOI: 10.1161/ATVBAHA.109.190405

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  37 in total

1.  Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women.

Authors:  Gavin J Blake; James D Otvos; Nader Rifai; Paul M Ridker
Journal:  Circulation       Date:  2002-10-08       Impact factor: 29.690

2.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

3.  Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study.

Authors:  J M Ordovas; L A Cupples; D Corella; J D Otvos; D Osgood; A Martinez; C Lahoz; O Coltell; P W Wilson; E J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-05       Impact factor: 8.311

4.  Low-density lipoprotein size, pravastatin treatment, and coronary events.

Authors:  H Campos; L A Moye; S P Glasser; M J Stampfer; F M Sacks
Journal:  JAMA       Date:  2001-09-26       Impact factor: 56.272

5.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.

Authors:  Robert S Rosenson; James D Otvos; David S Freedman
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

6.  Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans.

Authors:  Melissa A Austin; Philippa J Talmud; Federico M Farin; Deborah A Nickerson; Karen L Edwards; Donna Leonetti; Marguerite J McNeely; Hannah-Malia Viernes; Steve E Humphries; Wilfred Y Fujimoto
Journal:  Biochim Biophys Acta       Date:  2004-01-20

7.  Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study.

Authors:  S S Soedamah-Muthu; Y-F Chang; J Otvos; R W Evans; T J Orchard
Journal:  Diabetologia       Date:  2003-05-13       Impact factor: 10.122

8.  Loci for CETP, LPL, LIPC, and APOC3 affect plasma lipoprotein size and sub-population distribution in Hispanic and non-Hispanic white subjects: the Columbia University BioMarkers Study.

Authors:  S E Humphries; L Berglund; C R Isasi; J D Otvos; D Kaluski; R J Deckelbaum; S Shea; P J Talmud
Journal:  Nutr Metab Cardiovasc Dis       Date:  2002-08       Impact factor: 4.222

9.  Influence of common variants in the CETP, LPL, HL and APO E genes on LDL heterogeneity in healthy, middle-aged men.

Authors:  Camilla Skoglund-Andersson; Ewa Ehrenborg; Rachel M Fisher; Gunilla Olivecrona; Anders Hamsten; Fredrik Karpe
Journal:  Atherosclerosis       Date:  2003-04       Impact factor: 5.162

10.  Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study.

Authors:  Lewis Kuller; Alice Arnold; Russell Tracy; James Otvos; Greg Burke; Bruce Psaty; David Siscovick; David S Freedman; Richard Kronmal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-07-01       Impact factor: 8.311

View more
  70 in total

1.  Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib.

Authors:  Ronald M Krauss; Kathleen Wojnooski; Joseph Orr; J Casey Geaney; Cathy Anne Pinto; Yang Liu; John A Wagner; Julie Mabalot Luk; Amy O Johnson-Levonas; Matt S Anderson; Hayes M Dansky
Journal:  J Lipid Res       Date:  2011-12-17       Impact factor: 5.922

Review 2.  Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism.

Authors:  John J Albers; Simona Vuletic; Marian C Cheung
Journal:  Biochim Biophys Acta       Date:  2011-06-28

Review 3.  Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield.

Authors:  Russell M Medford; T Forcht Dagi; Robert S Rosenson; Margaret K Offermann
Journal:  Curr Atheroscler Rep       Date:  2013-05       Impact factor: 5.113

4.  Small dense LDL cholesterol and coronary heart disease: results from the Framingham Offspring Study.

Authors:  Masumi Ai; Seiko Otokozawa; Bela F Asztalos; Yasuki Ito; Katsuyuki Nakajima; Charles C White; L Adrienne Cupples; Peter W Wilson; Ernst J Schaefer
Journal:  Clin Chem       Date:  2010-04-29       Impact factor: 8.327

Review 5.  The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype.

Authors:  John D Brunzell; Alberto Zambon; Samir S Deeb
Journal:  Biochim Biophys Acta       Date:  2011-09-25

6.  From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus.

Authors:  Kiran Musunuru; Alanna Strong; Maria Frank-Kamenetsky; Noemi E Lee; Tim Ahfeldt; Katherine V Sachs; Xiaoyu Li; Hui Li; Nicolas Kuperwasser; Vera M Ruda; James P Pirruccello; Brian Muchmore; Ludmila Prokunina-Olsson; Jennifer L Hall; Eric E Schadt; Carlos R Morales; Sissel Lund-Katz; Michael C Phillips; Jamie Wong; William Cantley; Timothy Racie; Kenechi G Ejebe; Marju Orho-Melander; Olle Melander; Victor Koteliansky; Kevin Fitzgerald; Ronald M Krauss; Chad A Cowan; Sekar Kathiresan; Daniel J Rader
Journal:  Nature       Date:  2010-08-05       Impact factor: 49.962

7.  2009 World Congress on the Insulin Resistance Syndrome: cardiovascular disease concepts.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2010-07       Impact factor: 19.112

Review 8.  Atherogenic dyslipidemia: cardiovascular risk and dietary intervention.

Authors:  Kiran Musunuru
Journal:  Lipids       Date:  2010-06-04       Impact factor: 1.880

9.  New automated assay of small dense low-density lipoprotein cholesterol identifies risk of coronary heart disease: the Multi-ethnic Study of Atherosclerosis.

Authors:  Michael Y Tsai; Brian T Steffen; Weihua Guan; Robyn L McClelland; Russell Warnick; Joseph McConnell; Daniel M Hoefner; Alan T Remaley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-11-14       Impact factor: 8.311

Review 10.  Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef
Journal:  J Clin Endocrinol Metab       Date:  2012-09       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.